Publications

Publications

Scientific contributions highlighting the impact of Diatech Pharmacogenetics technologies in diagnostics.

Filter

All years 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2008
All product lines Easy Easy PGX Helix Microsatelliti Myriapod Myriapod NGS Realquant Response
  • Myriapod, Response

Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer. The Oncologist

  • Myriapod

Multiple and bilateral kidney tumors with clear cells of three different histotypes: A case report with clinicopathologic and molecular study. APMIS

  • Myriapod

Efficacy of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response in synchronous BRAF wild type-hepatocellular carcinoma: a case report. BMC Cancer

  • Easy

Aberrant expression of anaplastic lymphoma kinase in lung adenocarcinoma: Analysis of circulating free tumor RNA using one-step reverse transcription-polymerase chain reaction. Molecular Medicine Reports

GSTP1 Methylation and Protein Expression in Prostate Cancer: Diagnostic Implications. Disease Markers

  • Myriapod, Response

EGFR and KRAS mutational analysis in a large series of Italian non-small cell lung cancer patients: 2,387 cases from a single center. Oncology Reports

  • Myriapod

Genetic mutations in accordance with a low malignant potential tumour are not demonstrated in clear cell papillary renal cell carcinoma. Journal of Clinical Pathology

  • Response

Morphological features that can predict BRAFV600E-mutated carcinoma in paediatric thyroid cytology. Cytopathology

  • Response

Gastric GISTs: Analysis of c-Kit, PDGFRA and BRAF mutations in relation to prognosis and clinical pathological characteristics of patients – A GIRCG study. European Journal of Surgical Oncology

  • Myriapod

Maria Cecilia MengoliMalignant Pigmented Mass “Sequestrated” in the Lung: A Unique Case Report. Lung

Your next step starts here. Fill out the form and talk to us

Let's talk